Skip to main content

Growing prevalence of cancer to augment generic oncology sterile injectable market growth

 


Market Overview:

 

Generic oncology sterile injectable are widely used for the treatment of cancers prostate, breast, colorectal, melanoma, lung, and bronchus. They have the same active ingredients as that of the branded version, with only the inactive contents of the drugs being different.

 

Competitive Landscape:

Eli Lilly & Company, Biocon Ltd., Baxter International Inc., Hikma Pharmaceuticals PLC, Mylan N.V., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., and Pfizer Inc.

Key Market Drivers:

Growing prevalence of chronic disease such as breast, prostate, colorectal, melanoma, lung, and bronchus is driving growth of the generic oncology sterile injectable market. According to the World Health Organization, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths.

Increasing partnership and collaboration in the field of generic oncology sterile injectable is again fostering market growth. For instance, in February 2017 – Baxter International Inc. and ScinoPharm Taiwan, Ltd. announced a strategic partnership to develop, manufacture and commercialize five injectable drugs used in a range of cancer treatments, including lung cancer, multiple myeloma and breast cancer, as well as medication to treat nausea and vomiting, common side effects of chemotherapy.

Covid-19 Impact Analysis

Spread of Covid-19 has impacted the supply and demand of generic oncology sterile injectable. This is attributed to the imposed of lockdown and quarantine policies to curb the spread of infection.

Key Takeaways:

1.      The generic oncology sterile injectable market is expected to exhibit a CAGR of 11.5% over the forecast owing to the growing prevalence of cancer.

2.       North America is expected to gain significant growth over the forecast period owing to the growing initiatives by key players to expand production of generic oncology sterile. For instance, in July 2019, Nexus has entered into an agreement with Wisconsin’s village Pleasant Prairie for the development of a sterile injectable manufacturing facility.

 

Labels

Labels:

Comments

Post a Comment

Popular posts from this blog

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Analysis

  A primary driver for this market is the worldwide increase in occurrence of diabetes and cancer, across all age groups. According to the World Health Organization (WHO) 2018 statistics, the number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014. Moreover according to the World Health Organization cancer factsheet 2018, Cancer is the second leading cause of death globally, and is responsible for an estimated 9.6 million deaths in 2018.  Furthermore, increasing old age population is another driver, which is anticipated to create a high growth scenario for the market. As per the World Population Prospects 2019 revision, the number of people aged 80 years or over is projected to be triple, from 143 million in 2019 to 426 million in 2050. Alternatively, factors restraining the market are complications and risks associated with the treatment including diarrhea, nausea, hair loss, vomiting, severe infections, infertility, and heart complications....
Post a Comment
Read more

North America is expected to lead the global cosmetology market due to growing number of minimally invasive surgeries in the region

  Market Overview: Cosmetology is the field of a beauty practice that includes a variety of practices aimed at making individual’s look and feel their best. Competitive Landscape: GC Aesthetics, Mentor Worldwide LLC, Sientra Inc., Zimmer Holdings Inc., 3M Health Care, Allergan, Inc., Implantech Associates Inc., Institut Straumann AG, Nobel Biocare Holding AG, and Spectrum Designs Medical.   Key Market Drivers: An increasing number of cosmetic surgeries is expected to expand the global cosmetology market size. For instance, according to American Society of Plastic Surgeons (ASPS) 2017 reports, around 17.5 million cosmetic surgeries were performed in 2017, U.S. among which breast augmentation, liposuction, and nose reshaping were the top three procedures. High preferences for Botox surgeries which are used to reduce wrinkles and maintain youthful skin is again fostering the growth of the market growth. According to the same source, around 65% of women prefer Botul...
Post a Comment
Read more

Surgical Hemostats, Internal Tissue Sealants, and Adhesion Barriers Market is Expected to Grow Drastically, Assured By Experts From 2023 To 2028

  Surgical hemostat is a surgical tool used in many surgical procedures to control bleeding. Surgical hemostats covered in this report include thrombin-based, combination hemostats, oxidized regenerated cellulose-based, gelatin-based, and collagen-based. Internal tissue sealants are typically used in surgeries to bind or hold internal tissues such as blood vessels, internal organs, bone cartilage, dura matter and others. The global surgical hemostats, internal tissue sealants and adhesion barriers market is estimated to account for US$ 4,231.4 Mn in terms of value in 2020 and is expected to reach US$ 7,346.7 Mn by the end of 2027 Global Surgical Hemostats, Internal Tissue Sealants and Adhesion Barriers Market: Drivers Increasing number of surgical procedures is expected to propel growth of the global surgical  hemostats , internal tissue sealants and adhesion barriers market over the forecast period. For instance, according to ‘Surgical operations and procedures sta...
Post a Comment
Read more